Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashfaque Unwala

Cardiovascular Disease Mullica Hill, NJ Medical Doctor

NPI 1861447260 CMS profile 220654

698 Mullica Hill Rd Ste 330, Ste 330, Mullica Hill, NJ 08062

Open in the dashboard

General payments

$1,666

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashfaque Unwala of Mullica Hill, NJ is reported in the CMS Open Payments database as having received $1,666 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $336 15
2024 General $416 17
2023 General $299 14
2022 General $245 12
2021 General $142 8
2020 General $65 5
2019 General $162 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashfaque Unwala
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ashfaque Unwala were reported at $336. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ashfaque Unwala Cardiovascular Disease median Middle half National median
2019 $162 $450 $127–$1,392 $163
2020 $65 $242 $77–$751 $114
2021 $142 $335 $101–$1,037 $132
2022 $245 $395 $121–$1,211 $149
2023 $299 $443 $136–$1,283 $160
2024 $416 $450 $136–$1,323 $164
2025 $336 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $324 8 payments
  2. Novartis Pharmaceuticals Corporation $293 17 payments
  3. Medtronic, Inc. $172 8 payments
  4. Abiomed $153 6 payments
  5. E.R. Squibb & Sons, L.L.C. $116 7 payments
  6. Boston Scientific Corporation $55 1 payment
  7. Penumbra, Inc. $51 2 payments
  8. AstraZeneca Pharmaceuticals LP $49 4 payments
  9. Bard Peripheral Vascular, Inc. $47 2 payments
  10. Abbott Laboratories $46 2 payments
  11. Other $360 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,611 77 payments
  2. Grant $55 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $276 7 payments
  2. LEQVIO $251 14 payments
  3. LINQ II $111 3 payments
  4. Impella $102 4 payments
  5. ELIQUIS $63 4 payments
  6. ENTRESTO $63 4 payments
  7. VERQUVO $62 4 payments
  8. GENERAL - STENTS $55 1 payment
  9. CAMZYOS $53 3 payments
  10. Indigo System $51 2 payments
  11. Other $620 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

4,187

Median for Cardiology: 2,533

Drug cost

$420,016

Median for Cardiology: $485,213

Branded share of claims

15.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 139 $192,828
Xarelto Rivaroxaban Brand 62 $77,357
Repatha Sureclick Evolocumab Brand 21 $32,288
Entresto Sacubitril/Valsartan Brand 34 $26,541
Praluent Pen Alirocumab Brand 15 $16,171
Atorvastatin Calcium Generic 811 $12,657
Metoprolol Succinate Generic 506 $10,567
Ezetimibe Generic 221 $6,691
Dofetilide Generic 17 $5,750
Rosuvastatin Calcium Generic 199 $4,597

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$126,510

Medicare's payments for the services billed

Medicare patients

687

Average age 77

Services billed

1,494

331 women, 356 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 53%
Diabetes 49%
Atrial fibrillation 46%
Heart failure 44%
Chronic kidney disease 43%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $101
$101 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $45
$45 139 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $25
$25 34 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $19
$19 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record